The neuroscience company will use its Series C to move zalsupindole into Phase II clinical development and expand its pipeline of neuroplastogen therapies.
Delix Therapeutics has closed an oversubscribed $100 million Series C to advance its research into neuroplastogens, a class of compounds designed to promote changes in neural connections.
The financing, announced November 9, will support the clinical development of zalsupindole, the company's leading investigational treatment.
Delix is exploring therapies that aim to deliver some of the potential therapeutic effects associated with neuroplasticity without the hallucinogenic experiences associated with traditional psychedelics.
The company has completed early clinical development and is preparing a Phase IIb study in major depressive disorder, expected to begin in the first half of 2027.
The funds will also support additional research into neurological and psychiatric conditions.
The investment represents a bet on clinical development rather than an established commercial product.
Zalsupindole is not an approved treatment, and its effectiveness and safety still need to be demonstrated in larger clinical trials.
The next milestone will be generating clinical evidence showing whether the compound can deliver meaningful benefits for patients with depression.
Source: Fierce Biotech